Abstract # 2303 A Pretreatment PSA Level of 7 to 10 Ng/ml is an Independent Predictor of Adverse Biochemical Disease Free Survival among Low Risk Prostate Cancer Patients Treated with I-125 Brachytherapy

Presenter: Cesaretti, Jamie

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

From July 1991 to September 2005, a total of 585 patients were treated with I125 monotherapy for low risk prostate cancer (T1 or T2a, Gleason 6, PSA <10) without the use of hormone therapy. Implants were performed using the real‐time ultrasound‐guided seed‐placement method with modified peripheral loading. We analyzed the biochemical disease free survival outcomes of patients who had a minimum of 2 years of follow‐up (median follow‐up, 5 years; range, 2 to 13.8 years). Pretreatment factors analyzed included PSA level, T stage, era of treatment, age, Gleason score and dose to 90 percent of the prostate gland (D90). Biochemical disease free survival (bDFS) was determined using the Phoenix definition. bDFS was modeled using the Kaplan and Meier method and analyzed by both the log‐rank test and Cox regression analysis.